# Silicon Laboratories Inc.: financial statements, quarterly

SLAB · Nasdaq · CIK 1038074 · [Technology](/sectors/technology.md) · fiscal year ends Jan 2

Pages: [Overview](/companies/slab.md) · [Financials](/companies/slab/financials.md) · [Filings](/companies/slab/filings.md) · [Insiders](/companies/slab/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/slab/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-04-05) | Q2 FY2025 (2025-07-05) | Q3 FY2025 (2025-10-04) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [204](/filings/0001628280-24-045047.md) | [86.8 d](/filings/0001038074-26-000005.md) | [106](/filings/0001038074-25-000008.md) | [145](/filings/0001038074-25-000014.md) | [166](/filings/0001038074-25-000023.md) | [166 d](/filings/0001038074-26-000005.md) | [178](/filings/0001038074-26-000020.md) | [193](/filings/0001038074-26-000029.md) | [206](/filings/0001038074-25-000023.md) | [208 d](/filings/0001038074-26-000005.md) | [214](/filings/0001038074-26-000020.md) | [228](/filings/0001038074-26-000029.md) |
| Cost of revenue | $m | [84.7](/filings/0001628280-24-045047.md) | [42.9 d](/filings/0001038074-26-000005.md) | [51.3](/filings/0001038074-25-000008.md) | [68.8](/filings/0001038074-25-000014.md) | [76.1](/filings/0001038074-25-000023.md) | [76.0 d](/filings/0001038074-26-000005.md) | [79.9](/filings/0001038074-26-000020.md) | [84.7](/filings/0001038074-26-000029.md) | [87.0](/filings/0001038074-25-000023.md) | [76.1 d](/filings/0001038074-26-000005.md) | [86.5](/filings/0001038074-26-000020.md) | [87.5](/filings/0001038074-26-000029.md) |
| Gross profit | $m | [119](/filings/0001628280-24-045047.md) | [43.9 d](/filings/0001038074-26-000005.md) | [55.1](/filings/0001038074-25-000008.md) | [76.6](/filings/0001038074-25-000014.md) | [90.3](/filings/0001038074-25-000023.md) | [90.2 d](/filings/0001038074-26-000005.md) | [97.8](/filings/0001038074-26-000020.md) | [108](/filings/0001038074-26-000029.md) | [119](/filings/0001038074-25-000023.md) | [132 d](/filings/0001038074-26-000005.md) | [127](/filings/0001038074-26-000020.md) | [141](/filings/0001038074-26-000029.md) |
| Research and development | $m | [79.0](/filings/0001628280-24-045047.md) | [83.4 d](/filings/0001038074-26-000005.md) | [80.7](/filings/0001038074-25-000008.md) | [85.9](/filings/0001038074-25-000014.md) | [83.2](/filings/0001038074-25-000023.md) | [82.4 d](/filings/0001038074-26-000005.md) | [88.2](/filings/0001038074-26-000020.md) | [87.8](/filings/0001038074-26-000029.md) | [87.7](/filings/0001038074-25-000023.md) | [89.5 d](/filings/0001038074-26-000005.md) | [88.6](/filings/0001038074-26-000020.md) | [95.0](/filings/0001038074-26-000029.md) |
| Selling, general and administrative | $m | [27.8](/filings/0001628280-24-045047.md) | [33.6 d](/filings/0001038074-26-000005.md) | [33.6](/filings/0001038074-25-000008.md) | [38.7](/filings/0001038074-25-000014.md) | [36.8](/filings/0001038074-25-000023.md) | [36.4 d](/filings/0001038074-26-000005.md) | [41.6](/filings/0001038074-26-000020.md) | [43.2](/filings/0001038074-26-000029.md) | [43.7](/filings/0001038074-25-000023.md) | [45.8 d](/filings/0001038074-26-000005.md) | [55.5](/filings/0001038074-26-000020.md) | [56.3](/filings/0001038074-26-000029.md) |
| Operating income | $m | [12.2](/filings/0001628280-24-045047.md) | [(73.1) d](/filings/0001038074-26-000005.md) | [(59.1)](/filings/0001038074-25-000008.md) | [(48.0)](/filings/0001038074-25-000014.md) | [(29.7)](/filings/0001038074-25-000023.md) | [(28.6) d](/filings/0001038074-26-000005.md) | [(32.1)](/filings/0001038074-26-000020.md) | [(22.9)](/filings/0001038074-26-000029.md) | [(12.3)](/filings/0001038074-25-000023.md) | [(3.3) d](/filings/0001038074-26-000005.md) | [(17.1)](/filings/0001038074-26-000020.md) | [(10.7)](/filings/0001038074-26-000029.md) |
| Interest expense | $m | [1.4](/filings/0001104659-23-113394.md) | [0.9 d](/filings/0001104659-24-025535.md) | [0.5](/filings/0001628280-24-017536.md) | [0.3](/filings/0001038074-25-000014.md) | [0.3](/filings/0001038074-25-000023.md) | [0.3 d](/filings/0001038074-26-000005.md) | [0.3](/filings/0001038074-26-000020.md) | [0.3](/filings/0001038074-26-000029.md) | [0.2](/filings/0001038074-25-000023.md) | [0.2 d](/filings/0001038074-26-000005.md) | [0.2](/filings/0001038074-26-000020.md) | [0.3](/filings/0001038074-26-000029.md) |
| Income tax | $m | [3.4](/filings/0001628280-24-045047.md) | [(15.5) d](/filings/0001038074-26-000005.md) | [(0.4)](/filings/0001038074-25-000008.md) | [36.7](/filings/0001038074-25-000014.md) | [2.0](/filings/0001038074-25-000023.md) | [(2.1) d](/filings/0001038074-26-000005.md) | [1.9](/filings/0001038074-26-000020.md) | [2.5](/filings/0001038074-26-000029.md) | [0.4](/filings/0001038074-25-000023.md) | [2.2 d](/filings/0001038074-26-000005.md) | [2.2](/filings/0001038074-26-000020.md) | [2.2](/filings/0001038074-26-000029.md) |
| Net income | $m | [10.3](/filings/0001628280-24-045047.md) | [(69.8) d](/filings/0001038074-26-000005.md) | [(56.5)](/filings/0001038074-25-000008.md) | [(82.2)](/filings/0001038074-25-000014.md) | [(28.5)](/filings/0001038074-25-000023.md) | [(23.8) d](/filings/0001038074-26-000005.md) | [(30.5)](/filings/0001038074-26-000020.md) | [(21.8)](/filings/0001038074-26-000029.md) | [(9.9)](/filings/0001038074-25-000023.md) | [(2.7) d](/filings/0001038074-26-000005.md) | [(15.9)](/filings/0001038074-26-000020.md) | [(10.6)](/filings/0001038074-26-000029.md) |
| Diluted EPS | $ per share | [0.32](/filings/0001628280-24-045047.md) | not reported | [(1.77)](/filings/0001038074-25-000008.md) | [(2.56)](/filings/0001038074-25-000014.md) | [(0.88)](/filings/0001038074-25-000023.md) | not reported | [(0.94)](/filings/0001038074-26-000020.md) | [(0.67)](/filings/0001038074-26-000029.md) | [(0.30)](/filings/0001038074-25-000023.md) | not reported | [(0.48)](/filings/0001038074-26-000020.md) | [(0.32)](/filings/0001038074-26-000029.md) |
| Basic EPS | $ per share | [0.33](/filings/0001628280-24-045047.md) | not reported | [(1.77)](/filings/0001038074-25-000008.md) | [(2.56)](/filings/0001038074-25-000014.md) | [(0.88)](/filings/0001038074-25-000023.md) | not reported | [(0.94)](/filings/0001038074-26-000020.md) | [(0.67)](/filings/0001038074-26-000029.md) | [(0.30)](/filings/0001038074-25-000023.md) | not reported | [(0.48)](/filings/0001038074-26-000020.md) | [(0.32)](/filings/0001038074-26-000029.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-04-05) | Q2 FY2025 (2025-07-05) | Q3 FY2025 (2025-10-04) | FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [160](/filings/0001104659-23-113394.md) | [228](/filings/0001038074-25-000003.md) | [191](/filings/0001628280-24-017536.md) | [241](/filings/0001628280-24-032746.md) | [303](/filings/0001628280-24-045047.md) | [282](/filings/0001038074-26-000005.md) | [325](/filings/0001038074-25-000008.md) | [314](/filings/0001038074-25-000014.md) | [341](/filings/0001038074-25-000023.md) | [364](/filings/0001038074-26-000029.md) | [383](/filings/0001038074-26-000020.md) | [362](/filings/0001038074-26-000029.md) |
| Current assets | $m | [774](/filings/0001104659-23-113394.md) | [738](/filings/0001038074-25-000003.md) | [646](/filings/0001628280-24-017536.md) | [600](/filings/0001628280-24-032746.md) | [614](/filings/0001628280-24-045047.md) | [602](/filings/0001038074-26-000005.md) | [619](/filings/0001038074-25-000008.md) | [618](/filings/0001038074-25-000014.md) | [653](/filings/0001038074-25-000023.md) | [674](/filings/0001038074-26-000029.md) | [676](/filings/0001038074-26-000020.md) | [671](/filings/0001038074-26-000029.md) |
| Total assets | $m | [1,475](/filings/0001104659-23-113394.md) | [1,443](/filings/0001038074-25-000003.md) | [1,344](/filings/0001628280-24-017536.md) | [1,250](/filings/0001628280-24-032746.md) | [1,249](/filings/0001628280-24-045047.md) | [1,223](/filings/0001038074-26-000005.md) | [1,229](/filings/0001038074-25-000008.md) | [1,221](/filings/0001038074-25-000014.md) | [1,253](/filings/0001038074-25-000023.md) | [1,269](/filings/0001038074-26-000029.md) | [1,266](/filings/0001038074-26-000020.md) | [1,253](/filings/0001038074-26-000029.md) |
| Current liabilities | $m | [165](/filings/0001104659-23-113394.md) | [164](/filings/0001038074-25-000003.md) | [111](/filings/0001628280-24-017536.md) | [100](/filings/0001628280-24-032746.md) | [118](/filings/0001628280-24-045047.md) | [97.9](/filings/0001038074-26-000005.md) | [120](/filings/0001038074-25-000008.md) | [121](/filings/0001038074-25-000014.md) | [145](/filings/0001038074-25-000023.md) | [144](/filings/0001038074-26-000029.md) | [132](/filings/0001038074-26-000020.md) | [124](/filings/0001038074-26-000029.md) |
| Total liabilities | $m | [215](/filings/0001104659-23-113394.md) | [234](/filings/0001038074-25-000003.md) | [179](/filings/0001628280-24-017536.md) | [157](/filings/0001628280-24-032746.md) | [168](/filings/0001628280-24-045047.md) | [143](/filings/0001038074-26-000005.md) | [161](/filings/0001038074-25-000008.md) | [160](/filings/0001038074-25-000014.md) | [182](/filings/0001038074-25-000023.md) | [175](/filings/0001038074-26-000029.md) | [168](/filings/0001038074-26-000020.md) | [158](/filings/0001038074-26-000029.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,260](/filings/0001628280-24-045047.md) | [1,209](/filings/0001038074-26-000005.md) | [1,166](/filings/0001038074-25-000014.md) | [1,093](/filings/0001038074-25-000023.md) | [1,081](/filings/0001038074-25-000023.md) | [1,080](/filings/0001038074-26-000029.md) | [1,068](/filings/0001038074-26-000029.md) | [1,061](/filings/0001038074-26-000029.md) | [1,071](/filings/0001038074-25-000023.md) | [1,094](/filings/0001038074-26-000029.md) | [1,099](/filings/0001038074-26-000029.md) | [1,095](/filings/0001038074-26-000029.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-04-05) | Q2 FY2025 (2025-07-05) | Q3 FY2025 (2025-10-04) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(33.4) d](/filings/0001628280-24-045047.md) | [18.5 d](/filings/0001038074-26-000005.md) | [(71.8)](/filings/0001038074-25-000008.md) | [16.1 d](/filings/0001038074-25-000014.md) | [31.6 d](/filings/0001038074-25-000023.md) | [10.1 d](/filings/0001038074-26-000005.md) | [48.1](/filings/0001038074-26-000020.md) | [4.9 d](/filings/0001038074-26-000029.md) | [34.3 d](/filings/0001038074-25-000023.md) | [8.4 d](/filings/0001038074-26-000005.md) | [4.9](/filings/0001038074-26-000020.md) | [(14.5) d](/filings/0001038074-26-000029.md) |
| Capital expenditure | $m | [5.1 d](/filings/0001628280-24-045047.md) | [3.7 d](/filings/0001038074-26-000005.md) | [2.0](/filings/0001038074-25-000008.md) | [3.5 d](/filings/0001038074-25-000014.md) | [2.2 d](/filings/0001038074-25-000023.md) | [4.0 d](/filings/0001038074-26-000005.md) | [4.9](/filings/0001038074-26-000020.md) | [8.7 d](/filings/0001038074-26-000029.md) | [6.4 d](/filings/0001038074-25-000023.md) | [10.0 d](/filings/0001038074-26-000005.md) | [9.8](/filings/0001038074-26-000020.md) | [12.3 d](/filings/0001038074-26-000029.md) |
| Share repurchases | $m | [16.0 d](/filings/0001628280-24-045047.md) | [0.0 d](/filings/0001038074-26-000005.md) | [0.0](/filings/0001628280-24-017536.md) | [0.0 d](/filings/0001628280-24-032746.md) | [0.0 d](/filings/0001628280-24-045047.md) | [0.0 d](/filings/0001038074-26-000005.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-04-05) | Q2 FY2025 (2025-07-05) | Q3 FY2025 (2025-10-04) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [34.8](/filings/0001104659-23-113394.md) | [33.8](/filings/0001628280-24-017536.md) | [32.9](/filings/0001628280-24-032746.md) | [32.1](/filings/0001628280-24-045047.md) | [31.9](/filings/0001038074-25-000008.md) | [32.1](/filings/0001038074-25-000014.md) | [32.3](/filings/0001038074-25-000023.md) | [32.5](/filings/0001038074-26-000020.md) | [32.7](/filings/0001038074-26-000029.md) | [32.8](/filings/0001038074-25-000023.md) | [33.0](/filings/0001038074-26-000020.md) | [33.2](/filings/0001038074-26-000029.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,366,761 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001038074-26-000029.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.